Gallbladder Cancer Treatment in Hyderabad — Expert Oncology Care Across 7 Locations

Gallbladder cancer often causes no symptoms in its early stages — which is why it is so often found incidentally after routine surgery for gallstones. When symptoms do appear, the most common are: persistent pain or discomfort in the upper right abdomen; jaundice (yellowing of the skin and eyes, dark urine, pale stools) — which indicates the cancer has grown to block the bile duct; nausea, vomiting, and loss of appetite; unexplained weight loss; abdominal bloating; and fever without infection. Jaundice from gallbladder cancer is a sign of advanced disease and requires same-week specialist review and imaging.

Yes — gallbladder cancer is curable, but only when detected at a stage where surgery can remove it completely. Very early disease (Tis and T1a) is cured by simple cholecystectomy alone, with 5-year survival rates of 85–100%. T1b and T2 disease treated with radical cholecystectomy (liver wedge + lymphadenectomy) followed by adjuvant capecitabine has 5-year survival of 50–80%. The challenge is that most gallbladder cancers are not detected at these early stages. This is why incidental discovery after gallstone surgery — while alarming — actually represents a genuine opportunity for cure when followed by prompt specialist management.

The most important risk factor is gallstone disease — particularly large stones above 3cm. Gallstones cause chronic inflammation of the gallbladder lining, which over years increases cancer risk. Female gender (women have gallbladder cancer 2–3 times more often than men), obesity, chronic cholecystitis, porcelain gallbladder, gallbladder polyps above 1cm, and an abnormal pancreaticobiliary junction (a congenital condition causing reflux of pancreatic juice into the bile duct) are other established risk factors. India's high prevalence of gallstone disease explains its disproportionately high rate of gallbladder cancer compared to most of the world.

Incidental gallbladder cancer is cancer discovered unexpectedly in the pathology report after routine laparoscopic cholecystectomy for gallstones. The gallbladder is sent for standard pathological examination after every cholecystectomy — and in a small proportion of cases, cancer is found that was not suspected before the operation. What happens next depends on how deeply the cancer has grown through the gallbladder wall (the T stage). T1a cancers are cured by the initial operation alone. T1b and above require a second, more extensive operation — revision surgery — to remove liver tissue, lymph nodes, and the laparoscopic port sites. If you have received a pathology report after gallstone surgery that mentions cancer, this requires urgent oncology review within 2–4 weeks.

Radical cholecystectomy is the correct surgical operation for gallbladder cancer from T1b onwards. It involves removing: the gallbladder; a wedge of liver tissue adjacent to the gallbladder (or formal liver segment IVb + V resection for deeper tumours); all regional (portal) lymph nodes between the liver and pancreas; and sometimes part of the bile duct if it is involved. For incidental gallbladder cancer found after laparoscopic surgery, the laparoscopic port sites are also excised. Simple cholecystectomy — removing just the gallbladder — is not sufficient treatment for T1b and above, because cancer cells in the gallbladder wall or surrounding tissue will be left behind and the cancer will recur.

Survival rates depend critically on stage at diagnosis. Tis/T1a: 5-year survival 85–100% with simple cholecystectomy. T1b: 70–80% with radical cholecystectomy. T2 (Stage II): 50–70% with radical surgery and adjuvant capecitabine. T3 (Stage III): 20–40% with extended radical resection. Stage IV (distant spread): 5–15%. The poor overall survival statistics often quoted for gallbladder cancer reflect the fact that most patients are diagnosed at Stage III or Stage IV, when curative surgery is no longer possible. For patients diagnosed at early stages — including incidental discovery after gallstone surgery — outcomes are considerably better.

For advanced (unresectable or metastatic) gallbladder cancer, systemic chemotherapy with gemcitabine and cisplatin is the standard first-line treatment, based on the ABC-02 trial demonstrating improved overall survival compared to gemcitabine alone. Treatment typically continues for 6 months and is monitored with regular CT scans and tumour markers. For patients with jaundice from bile duct obstruction, biliary stenting (ERCP) is placed before chemotherapy to restore bile flow. Molecular testing of the tumour (FGFR2, IDH1, HER2, MSI-H) is arranged to identify patients eligible for targeted therapies at progression. Alongside chemotherapy, comprehensive palliative care manages pain, nutrition, and quality of life.

Yes — the liver is the most common site of gallbladder cancer spread, because the gallbladder sits directly against the liver bed. The cancer can grow through the gallbladder wall into adjacent liver tissue (T3 local invasion) or spread through the portal blood supply to form liver metastases (Stage IV). This is why the correct surgery for gallbladder cancer includes removal of a wedge of liver tissue alongside the gallbladder — not just the gallbladder itself. When cancer has spread widely through the liver, surgery is no longer curative and systemic chemotherapy becomes the primary treatment.

Costs in Hyderabad vary by stage and treatment. Radical cholecystectomy with liver wedge and lymphadenectomy costs approximately ₹2,50,000 to ₹6,00,000. Extended resection for T3 disease (liver segment IVb+V) costs ₹4,00,000 to ₹9,00,000. Revision surgery for incidental GBC costs ₹3,00,000 to ₹7,00,000. Adjuvant capecitabine (6-month oral course) costs ₹30,000 to ₹90,000 in total. Gemcitabine + cisplatin (IV chemotherapy for advanced disease) costs ₹30,000 to ₹80,000 per cycle. CION provides a personalised cost estimate after your initial oncology consultation. EMI payment options are available for all patients.

Absolutely — and for gallbladder cancer, a second opinion is particularly important in two situations. First, if you have received an incidental GBC diagnosis after gallstone surgery and been told no further treatment is needed — for T1b and above, this is almost certainly incorrect; revision surgery is required. Second, if advanced disease has been declared inoperable — the line between resectable and unresectable gallbladder cancer can be narrow and is best assessed by a surgical oncologist experienced specifically in hepatobiliary surgery. CION offers a dedicated Second Opinion service where our tumour board reviews your imaging, pathology, and existing recommendation before advising on the appropriate pathway forward.